journal article·2019-06-19

Mixed Mucoadhesive Amphiphilic Polymeric Nanoparticles Cross a Model of Nasal Septum Epithelium in Vitro

Inbar Schlachet, Alejandro Sosnik

ACS Applied Materials & Interfaces· Volume 11· Issue 24
Publisher page

Abstract

Intranasal administration of nano-drug-delivery systems emerged as an appealing strategy to surpass the blood-brain barrier and thus increase drug bioavailability in the central nervous system. However, a systematic study of the effect of the structural properties of the nanoparticles on the nose-to-brain transport is missing. In this work, we synthesized and characterized mixed amphiphilic polymeric nanoparticles combining two mucoadhesive graft copolymers, namely, chitosan- g-poly(methyl methacrylate) and poly(vinyl alcohol)- g-poly(methyl methacrylate), for the first time. Chitosan enables the physical stabilization of the nanoparticles by ionotropic cross-linking with tripolyphosphate and confers mucoadhesiveness, while poly(vinyl alcohol) is also mucoadhesive and, owing to its nonionic nature, it improves nanoparticle compatibility in nasal epithelial cells by reducing the surface charge of the nanoparticles. After a thorough characterization of the mixed nanoparticles by dynamic light scattering and nanoparticle tracking analysis, we investigated the cell uptake by fluorescence light and confocal microscopy and imaging flow cytometry. Mixed nanoparticles were readily internalized at 37 °C, while the uptake was inhibited almost completely at 4 °C, indicating the involvement of energy-dependent mechanisms. Finally, we assessed the nanoparticle permeability across liquid-liquid and air-liquid monolayers of a nasal septum epithelial cell line and studied the effect of nanoparticle concentration and temperature on the apparent permeability. Overall, our findings demonstrate that these novel amphiphilic nanoparticles cross this in vitro model of intranasal epithelium mainly by a passive (paracellular) pathway involving the opening of epithelial tight junctions.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Nanocomposite Films for Food Packaging · Surfactants and Colloidal Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratory of Pharmaceutical Nanomaterials Science, Department of Materials Science and Engineering, Technion—Israel Institute of Technology, Technion City, Haifa 3200003, Israel

Funding

Israel Science Foundation · Teva Pharmaceutical Industries · Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology

References (75)

Show source-provided references
1. 10.1067/mai.2000.10905610.1067/mai.2000.109056 ↗
2. 10.1007/s12016-010-8206-210.1007/s12016-010-8206-2 ↗
3. 10.1111/j.1365-2249.2009.04010.x10.1111/j.1365-2249.2009.04010.x ↗
4. 10.1016/j.ijpharm.2007.03.02510.1016/j.ijpharm.2007.03.025 ↗
5. 10.2174/15672011280352982810.2174/156720112803529828 ↗
6. 10.1001/archotol.134.6.64310.1001/archotol.134.6.643 ↗
7. 10.1023/B:PHAR.0000026823.82950.ff10.1023/B:PHAR.0000026823.82950.ff ↗
8. 10.1016/j.pharmthera.2012.03.00310.1016/j.pharmthera.2012.03.003 ↗
9. 10.1016/S0169-409X(97)00060-410.1016/S0169-409X(97)00060-4 ↗
10. 10.1016/j.ijpharm.2009.06.01910.1016/j.ijpharm.2009.06.019 ↗
11. 10.1021/mp900275s10.1021/mp900275s ↗
12. 10.3390/pharmaceutics1001003410.3390/pharmaceutics10010034 ↗
13. 10.2174/221173851130102000510.2174/2211738511301020005 ↗
14. 10.1016/j.ijbiomac.2014.03.02210.1016/j.ijbiomac.2014.03.022 ↗
15. 10.2217/nnm.12.10410.2217/nnm.12.104 ↗
16. 10.2147/IJN.S14548810.2147/IJN.S145488 ↗
17. 10.1002/jps.2383610.1002/jps.23836 ↗
18. 10.1080/10717544.2016.122321610.1080/10717544.2016.1223216 ↗
19. 10.1016/j.lfs.2016.08.03310.1016/j.lfs.2016.08.033 ↗
20. 10.1016/j.biopha.2017.07.06710.1016/j.biopha.2017.07.067 ↗
21. 10.1080/0363904080236370410.1080/03639040802363704 ↗
22. 10.1016/j.ijpharm.2008.03.02910.1016/j.ijpharm.2008.03.029 ↗
23. 10.1016/j.biotechadv.2015.01.00310.1016/j.biotechadv.2015.01.003 ↗
24. 10.1039/C3RA47370H10.1039/C3RA47370H ↗
25. 10.1155/2013/34031510.1155/2013/340315 ↗
26. 10.2217/nnm.15.19110.2217/nnm.15.191 ↗
27. 10.1016/j.carbpol.2019.02.02210.1016/j.carbpol.2019.02.022 ↗
28. 10.1039/C7BM00675F10.1039/C7BM00675F ↗
29. 10.3390/polym1005047810.3390/polym10050478 ↗
30. 10.1211/002235702253910.1211/0022357022539 ↗
31. FDA FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm632761.htm (accessed in March, 2019).
32. Aegis Awarded Patent for Intranasal Administration of Active Agents to the Central Nervous System, 2014, https://www.marketwatch.com/press-release/aegis-awarded-patent-for-intranasal-administration-of-active-agents-to-the-central-nervous-system-2014-11-12 (accessed in March, 2019).
33. Teleflex VaxINator. http://www.vaxinator.com/ (accessed in March, 2019).
34. 10.1211/002235701177514510.1211/0022357011775145 ↗
35. 10.1016/j.addr.2005.07.00910.1016/j.addr.2005.07.009 ↗
36. 10.1016/j.progpolymsci.2014.07.01010.1016/j.progpolymsci.2014.07.010 ↗
37. 10.1016/j.lfs.2017.12.02510.1016/j.lfs.2017.12.025 ↗
38. 10.1007/s11095-011-0440-710.1007/s11095-011-0440-7 ↗
39. 10.1016/0378-5173(92)90235-T10.1016/0378-5173(92)90235-T ↗
40. 10.1016/S0169-409X(97)00061-610.1016/S0169-409X(97)00061-6 ↗
41. 10.1023/A:101621023112110.1023/A:1016210231121 ↗
42. 10.1080/1071754050017700910.1080/10717540500177009 ↗
43. 10.1016/j.tiv.2004.07.00310.1016/j.tiv.2004.07.003 ↗
44. 10.1111/j.2042-7158.2012.01540.x10.1111/j.2042-7158.2012.01540.x ↗
45. Sosnik, A. Issue-Based in Vitro and Ex Vivo Models for Nasal Permeability Studies; Sarmento, B., Ed. Elsevier Ltd, 2015; pp 237–254.10.1016/B978-0-08-100094-6.00014-6 ↗
46. 10.1021/mp200572t10.1021/mp200572t ↗
47. 10.1016/j.biomaterials.2012.09.08210.1016/j.biomaterials.2012.09.082 ↗
48. 10.1016/j.biomaterials.2012.05.01310.1016/j.biomaterials.2012.05.013 ↗
49. 10.1016/j.addr.2009.09.00410.1016/j.addr.2009.09.004 ↗
50. Kong X. · Int. J. Clin. Exp. Med. · 2015 · 8 · 3498
51. 10.1023/B:PHAM.0000016249.52831.a510.1023/B:PHAM.0000016249.52831.a5 ↗
52. 10.1021/js960182o10.1021/js960182o ↗
53. 10.3748/wjg.v11.i33.513610.3748/wjg.v11.i33.5136 ↗
54. 10.1021/cr030441b10.1021/cr030441b ↗
55. 10.3389/fphys.2012.0032110.3389/fphys.2012.00321 ↗
56. 10.3109/02652048.2011.65150010.3109/02652048.2011.651500 ↗
57. 10.1002/jbm.b.3330110.1002/jbm.b.33301 ↗
58. 10.1038/sj.eye.670029010.1038/sj.eye.6700290 ↗
59. 10.1615/JLongTermEffMedImplants.v15.i6.6010.1615/JLongTermEffMedImplants.v15.i6.60 ↗
60. 10.1016/j.jcot.2013.11.00510.1016/j.jcot.2013.11.005 ↗
61. 10.1039/C5TB00594A10.1039/C5TB00594A ↗
62. 10.2133/dmpk.20.43510.2133/dmpk.20.435 ↗
63. 10.1016/j.protcy.2016.05.20610.1016/j.protcy.2016.05.206 ↗
64. 10.1016/j.jconrel.2005.09.03410.1016/j.jconrel.2005.09.034 ↗
65. 10.1016/j.ijpharm.2016.09.08610.1016/j.ijpharm.2016.09.086 ↗
66. 10.1007/s10616-012-9493-710.1007/s10616-012-9493-7 ↗
67. 10.1016/j.colsurfb.2015.10.03610.1016/j.colsurfb.2015.10.036 ↗
68. International Organization for Standardization. ISO 10993-5:2009 Biological Evaluation of Medical Devices Part 5: Tests for in Vitro Cytotoxicity, 2009. https://www.iso.org/standard/36406.html (accessed in May, 2019).
69. 10.4155/tde.14.6710.4155/tde.14.67 ↗
70. 10.1002/jps.2103110.1002/jps.21031 ↗
71. 10.1016/j.ejpb.2016.07.01010.1016/j.ejpb.2016.07.010 ↗
72. 10.1016/j.ejpb.2009.08.00810.1016/j.ejpb.2009.08.008 ↗
73. 10.1039/C6BM00667A10.1039/C6BM00667A ↗
74. 10.1016/j.tiv.2007.07.00710.1016/j.tiv.2007.07.007 ↗
75. 10.1124/jpet.118.25467210.1124/jpet.118.254672 ↗